CSL Receives FTC Request for Additional Information

CSL Receives FTC Request for Additional Information

Melbourne, Australia — 13/10/2008

CSL Receives FTC Request for Additional Information on its Proposed Merger with Talecris Biotherapeutics.

CSL Limited today announced that it has received a request for additional information, commonly referred to as a Second Request, from the U.S. Federal Trade Commission (“FTC”) regarding its proposed acquisition of Talecris Biotherapeutics, which was announced on August 13, 2008.

Download this release: CSL Receives FTC Request

For further information, please contact:

Media Contacts
Dr Rachel David
Director of Public Affairs
Phone: 0401 775 779

Investor Contact
Mark Dehring
Director of Investor Relations
Phone: +61 3 9389 2818
Email: mark.dehring@csl.com.au
© 2016 CSL Limited